New anticoagulants in the treatment of venous thrombo-embolic disease;Les nouveaux anticoagulants dans la maladie thromboembolique veineuse

Revue de Medecine Interne

Volumn 24, Issue 11, 2003, Pages 738-744

  Bura Riviere, A ^a   Fiessinger, J N ^a  

^a HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

Anticoagulants; Antithrombin; Deep venous thrombosis; Low molecular weight heparin

Indexed keywords

ANTICOAGULANT AGENT; ENOXAPARIN; FONDAPARINUX; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; WARFARIN; XIMELAGATRAN;

ANTICOAGULATION; BLEEDING; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DRUG EFFICACY; HUMAN; LUNG EMBOLISM; PHASE 3 CLINICAL TRIAL; REVIEW; THROMBOEMBOLISM;

EID: 0242428302     PISSN: 02488663     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0248-8663(03)00252-2     Document Type: Short Survey

References (19)

1. Hyers TM, Agnelli G, Hull RD, Morris TA, Samama M, Tapson VF, et al. Antithrombotic therapy for venous thromboembolic disease. Circulation 2001;119:176S-93S.
2. Warkentin TE, Levine MN, Hirsh J, Horsewood P, Roberts RS, Gent M, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995;332:1330-5.
3. Lagerstedt CI, Olsson CG, Fagher BO, Oqvist BW, Albrechtsson U. Need for long-term anticoagulant treatment in symptomatic calf-vein thrombosis. Lancet 1985;2:515-8.
4. Prins MH, Hutten BA, Koopman MM, Buller HR. Long-term treatment of venous thromboembolic disease. Thromb Haemost 1999;82:892-8.
5. Gitter MJ, Jaeger TM, Petterson TM, Gersh BJ, Silverstein MD. Bleeding and thromboembolism during anticoagulant therapy: a population based study in Rochester, Minnesota. Mayo Clin Proc 1995;70:725-33.
6. Palareti G, Leali N, Coccheri S, Poggi M, Manotti C, D'Angelo A, et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. Lancet 1996;348:423-8.
7. Steffensen FH, Kristensen K, Ejlersen E, Dahlerup JF, Sorensen HT. Major haemorrhagic complications during oral anticoagulant therapy in a Danish population-based cohort. J Intern Med 1997;242:497-503.
8. Turpie AG, Bauer KA, Eriksson BI, Lassen MR. Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial. Lancet 2002;359:1721-6.
9. Lassen MR, Bauer KA, Eriksson BI, Turpie AG. Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison. Lancet 2002;359:1715-20.
10. Eriksson BI, Bauer KA, Lassen MR, Turpie AG. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. N Engl J Med 2001;345:1298-304.
11. Bauer KA, Eriksson BI, Lassen MR, Turpie AG. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. N Engl J Med 2001;345:1305-10.
12. Turpie AG, Gallus AS, Hoek JA. A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement. N Engl J Med 2001;344:619-25.
13. Turpie AGG, Bauer KA, Eriksson BI, Lassen MR, for the Steering Committees of the Pentasaccharide Orthopedic Prophylaxis Studies. Fondaparinux vs Enoxaparin for the Prevention of Venous Thromboembolism in Major Orthopedic Surgery: a Meta-analysis of 4 Randomized Double-blind Studies. Arch Intern Med 2002;162:1833-40.
14. Bounameaux H, Perneger T. Fondaparinux: a new synthetic pentasaccharide for thrombosis prevention. Lancet 2002;359:1710-1.
15. Eriksson H, Eriksson UG, Frison L, Hansson PO, Held P, Holmstrom M, et al. Pharmacokinetics and pharmacodynamics of melagatran, a novel synthetic LMW thrombin inhibitor, in patients with acute DVT. Thromb Haemost 1999;81:358-63.
16. Gustafsson D, Nystrom J, Carlsson S, Bredberg U, Eriksson U, Gyzander E, et al. The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: intestinal absorption properties, biochemical and pharmacodynamic effects. Thromb Res 2001;101:171-81.
17. Eriksson BI, Arfwidsson AC, Frison L, Eriksson UG, Bylock A, Kalebo P, et al. A dose-ranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip or knee replacement: METHRO I. MElagatran for THRombin inhibition in Orthopaedic surgery. Thromb Haemost 2002;87:231-7.
18. Francis CW, Davidson BL, Berkowitz SD, Lotke PA, Ginsberg JS, Lieberman JR, et al. Ximelagatran versus warfarin for the prevention of venous thromboembolism after total knee arthroplasty. A randomized, double-blind trial. Ann Intern Med 2002;137:648-55.
19. Eriksson H, Wåhlander K, Gustafsson D, Welin Lt, Frison L, Schulman S. A randomized, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: Thrive I. Journal of Thrombosis and Haemostasis 2003;1:41-7.